In a phase 2 study, iptacopan — an oral, highly potent proximal complement inhibitor — reduced proteinuria in patients with IgA nephropathy. New research findings from a phase 3 trial are ...

The new data – in rare kidney disease IgA nephropathy (IgAN) – comes from the APPLAUSE-IgAN study, with iptacopan achieving a "clinically meaningful and highly statistically significant ...

Iptacopan has already been shown to work ... and just a few das ago reported a mid-stage trial win in rare kidney disease IgA nephropathy (IgAN), in which it also has a phase 3 trial of the ...

Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

But for sure, individuals diagnosed with IgA nephropathy should be treated with ... right now with a recent accelerated approval of iptacopan (Fabhalta, Novartis) as one of these potential ...

The lead indication for the Alpine drug, povetacicept, is the chronic kidney disease IgA nephropathy. Novartis’s iptacopan met the first of two main goals in its pivotal study in immunoglobulin ...